# Online Generic Medicine/www.onlinegenericmedicine.com – FDA Warning Letter, Sep 2, 2026

Source: https://www.keypedia.com/records/warning_letter/online-generic-medicinewwwonlinegenericmedicinecom/3a86c2fb-20a3-48f8-9c02-9fae76dec430

> FDA WARNING_LETTER for Online Generic Medicine/www.onlinegenericmedicine.com on September 02, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: Online Generic Medicine/www.onlinegenericmedicine.com
- Inspection Date: 2026-09-02
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Summary: On September 23, 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to Online Generic Medicine (www.onlinegenericmedicine.com) following website reviews conducted on August 26 and September 2, 2026. The FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act related to the sale of unapproved and misbranded injectable drugs. The primary violation involves the unauthorized sale of Semanat Injection, a version of semaglutide. The FDA determined this product is an unapproved new drug that lacks the necessary safety and effectiveness reviews required by law. Additionally, the drug is considered misbranded because its labeling fails to provide adequate directions for safe use and it is being sold without a required prescription from a licensed healthcare professional. The FDA highlighted that injectable drugs sold without oversight pose severe risks, including potential contamination and life-threatening infections like sepsis. Furthermore, these products bypass critical safety information, such as the black box warnings required for approved semaglutide products regarding thyroid tumor risks. Online Generic Medicine is required to immediately stop offering these unapproved drugs to U.S. consumers. The company must provide a written response to the FDA within 15 business days outlining the specific steps taken to correct the violations and the measures implemented to prevent their recurrence. Failure to address these issues may result in legal action, such as product seizures or injunctions.

## Related Officers

- [Director](https://www.keypedia.com/people/sangeeta-vaswani-chatterjee/3102421f-4b0b-4860-ab17-b6bdafecd2c8)

Company: https://www.keypedia.com/companies/online-generic-medicinewwwonlinegenericmedicinecom/87e0dab1-e925-4737-9fc3-c1d3c814072e

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c